CO2022009078A2 - Tratamiento para sobrecarga fisiologica de hierro - Google Patents

Tratamiento para sobrecarga fisiologica de hierro

Info

Publication number
CO2022009078A2
CO2022009078A2 CONC2022/0009078A CO2022009078A CO2022009078A2 CO 2022009078 A2 CO2022009078 A2 CO 2022009078A2 CO 2022009078 A CO2022009078 A CO 2022009078A CO 2022009078 A2 CO2022009078 A2 CO 2022009078A2
Authority
CO
Colombia
Prior art keywords
iron
mtp
treatment
iron overload
reduces
Prior art date
Application number
CONC2022/0009078A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Wake
Volker Germaschewski
Igor Theurl
Jonathan Leslie Papworth
Delphine Meynard
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917524.9A external-priority patent/GB201917524D0/en
Priority claimed from GBGB1917882.1A external-priority patent/GB201917882D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of CO2022009078A2 publication Critical patent/CO2022009078A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
CONC2022/0009078A 2019-11-29 2022-06-29 Tratamiento para sobrecarga fisiologica de hierro CO2022009078A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1917524.9A GB201917524D0 (en) 2019-11-29 2019-11-29 Treatment for physiological iron overload
GBGB1917882.1A GB201917882D0 (en) 2019-12-06 2019-12-06 Treatment for physiological iron overload
PCT/EP2020/083677 WO2021105389A1 (en) 2019-11-29 2020-11-27 Treatment for physiological iron overload

Publications (1)

Publication Number Publication Date
CO2022009078A2 true CO2022009078A2 (es) 2022-09-20

Family

ID=73698783

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009078A CO2022009078A2 (es) 2019-11-29 2022-06-29 Tratamiento para sobrecarga fisiologica de hierro

Country Status (12)

Country Link
US (1) US12570740B2 (enExample)
EP (1) EP4065607A1 (enExample)
JP (2) JP7709436B2 (enExample)
KR (1) KR20220107252A (enExample)
CN (2) CN115380049B (enExample)
BR (1) BR112022010424A2 (enExample)
CA (1) CA3162880A1 (enExample)
CO (1) CO2022009078A2 (enExample)
IL (1) IL293314A (enExample)
MX (1) MX2022006495A (enExample)
PH (1) PH12022551299A1 (enExample)
WO (1) WO2021105389A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) * 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN113667600B (zh) * 2021-07-21 2023-08-11 青岛海特生物医疗有限公司 用于二氧化碳培养箱功率分配的方法、装置及二氧化碳培养箱
WO2026019448A1 (en) * 2024-07-16 2026-01-22 Rallybio Ipe Llc Treatment of pathologies associated with beta-thalassemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2005023835A2 (en) * 2003-09-09 2005-03-17 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) * 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
CN105219780B (zh) 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用

Also Published As

Publication number Publication date
EP4065607A1 (en) 2022-10-05
CN115380049A (zh) 2022-11-22
CA3162880A1 (en) 2021-06-03
JP7709436B2 (ja) 2025-07-16
JP2023503513A (ja) 2023-01-30
BR112022010424A2 (pt) 2022-08-23
PH12022551299A1 (en) 2023-11-20
JP7862652B2 (ja) 2026-05-19
JP2025166832A (ja) 2025-11-06
IL293314A (en) 2022-07-01
KR20220107252A (ko) 2022-08-02
MX2022006495A (es) 2022-09-07
CN122427287A (zh) 2026-07-21
US20230025129A1 (en) 2023-01-26
US12570740B2 (en) 2026-03-10
WO2021105389A1 (en) 2021-06-03
CN115380049B (zh) 2026-03-27

Similar Documents

Publication Publication Date Title
MX2023001689A (es) Inhibidores de bcl-2.
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
EA201001523A1 (ru) Ингибиторы матриксной металлопротеазы на основе арилсульфонамида
MX2019011795A (es) Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica.
EA201000920A1 (ru) Ингибиторы пролилгидроксилазы
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
EA200900571A1 (ru) Композиции chk1 ингибиторов
PH12022551299A1 (en) Treatment for physiological iron overload
MY138732A (en) Conjugated complement cascade inhibitors
MX395085B (es) Tratamiento conjunto contra tipos de cancer hematologico.
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
CL2025001501A1 (es) Inhibidores de proteasas para tratar o prevenir la infección por coronavirus.
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
CL2020002505A1 (es) Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk
MX2019002259A (es) Inhibicion de la actividad de la olig2.
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
BR112022022845A2 (pt) Tratamento de efeitos adversos causados por antipsicóticos atípicos
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2
ECSP22076176A (es) Preparaciones sólidas orales
ECSP21042779A (es) Moduladores de la expresión de irf5